What is VTAK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VTAK?

P/E (TTM) is n/a and 52-week range is $0.82 to $30.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VTAK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VTAK?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-1.69B, EPS (TTM) near $-7.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Catheter Precision Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fort Mill, South Carolina, US, 3.6M shares outstanding, ISIN US74933X7084 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Catheter Precision Inc

$VTAK

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.98

+11.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Catheter Precision, Inc. engages in the design, manufacture, and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 17 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. Its two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is also a technology-enabled regional air mobility company.

Employees

Website

www.ramed.com/

IPO

2018-09-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)